In May 2019 CMS issued a final rule that expanded step therapy to Medicare Part B drugs but specifies that antineoplastics are to remain among the “protected classes,” and that insurers could impose prior authorization and step therapy requirements for new patients only.
As cancer treatments have become increasingly targeted and complex, the potential for increased utilization of step therapy in oncology presents unique challenges for patients and providers. This lecture series explores the implications for patient-centered care of implementation of step therapy in Medicare Advantage plans, which cover more than 20 million Medicare beneficiaries.
For more information on this project, please contact the ACCC Provider Education department.
This project is sponsored by Amgen.
